Finance in pharma
What makes pharma finance distinctive: R&D as a risky capital allocation, patent-cliff revenue dynamics, pricing and reimbursement, and how the numbers differ from other industries.
Pharmaceutical finance runs on a distinct economic model: enormous upfront R&D spend, long development timelines, patent-driven revenue cliffs, and asymmetric risk-reward across a drug pipeline. This block applies core corporate finance to that reality, showing how valuation, capital allocation, and profitability analysis differ when a single Phase III failure can erase billions in value while an approval can create them. You will work through the financial metrics analysts and executives actually track, from R&D intensity to peak sales projections, benchmarked against US and European industry norms. The block closes with the regulatory and risk framework, including pricing controls, IP litigation exposure, and the due-diligence checks needed before financing, licensing, or acquiring pharmaceutical assets.
What you'll master
- Build and interpret a pipeline valuation using risk-adjusted NPV across clinical phases
- Calculate and benchmark sector-specific ratios like R&D-to-sales, gross margin, and patent cliff exposure
- Assess the financial impact of pricing regulation and reimbursement systems on projected revenues across US and EU markets
- Conduct a financial due-diligence review of a licensing deal or M&A target, flagging IP, regulatory, and litigation risks